Literature DB >> 10620181

Renal abnormalities in sickle cell disease.

P T Pham1, P C Pham, A H Wilkinson, S Q Lew.   

Abstract

Renal abnormalities in sickle cell disease. Sickle cell nephropathy is indicated by sickled erythrocytes, with the consequent effects of decreased medullary blood flow, ischemia, microinfarct and papillary necrosis. Impaired urinary concentrating ability, renal acidification, hematuria, and potassium secretion are also found. There may be a causal relationship between an increase in nitric oxide synthesis and experimental sickle cell nephropathy, and some studies have indicated that the progression of sickle cell nephropathy is hemodynamically mediated. Although there are many studies showing that proteinuria, nephrotic syndrome, chronic progressive renal failure, and acute renal failure syndromes are the outcome of this disease, the pathogenic mechanism(s) and potential therapies remain to be elucidated. Survival of patients with sickle cell nephropathy who progress to end-stage renal disease (ESRD) is equal to non-diabetic ESRD patients, and graft survival rates are also similar for those who undergo renal transplantation. This article presents a historical review of the glomerular and tubular disorders associated with sickle cell nephropathy, and reviews therapeutic indications to slow its progression. Further research is needed.

Entities:  

Mesh:

Year:  2000        PMID: 10620181     DOI: 10.1046/j.1523-1755.2000.00806.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  51 in total

1.  Biomarkers for early detection of sickle nephropathy.

Authors:  Nambirajan Sundaram; Michael Bennett; Jamie Wilhelm; Mi-Ok Kim; George Atweh; Prasad Devarajan; Punam Malik
Journal:  Am J Hematol       Date:  2011-05-31       Impact factor: 10.047

Review 2.  The role of CD47 in pathogenesis and treatment of renal ischemia reperfusion injury.

Authors:  Jeffrey S Isenberg; David D Roberts
Journal:  Pediatr Nephrol       Date:  2018-11-03       Impact factor: 3.714

Review 3.  Sickle cell disease: renal manifestations and mechanisms.

Authors:  Karl A Nath; Robert P Hebbel
Journal:  Nat Rev Nephrol       Date:  2015-02-10       Impact factor: 28.314

4.  Anomalous renal effects of tin protoporphyrin in a murine model of sickle cell disease.

Authors:  Julio P Juncos; Joseph P Grande; Narayana Murali; Anthony J Croatt; Luis A Juncos; Robert P Hebbel; Zvonimir S Katusic; Karl A Nath
Journal:  Am J Pathol       Date:  2006-07       Impact factor: 4.307

5.  Management of Hematuria in Children.

Authors:  O N Ray Bignall; Bradley P Dixon
Journal:  Curr Treat Options Pediatr       Date:  2018-06-14

6.  Oxidative stress and induction of heme oxygenase-1 in the kidney in sickle cell disease.

Authors:  K A Nath; J P Grande; J J Haggard; A J Croatt; Z S Katusic; A Solovey; R P Hebbel
Journal:  Am J Pathol       Date:  2001-03       Impact factor: 4.307

7.  Transgenic sickle mice are markedly sensitive to renal ischemia-reperfusion injury.

Authors:  Karl A Nath; Joseph P Grande; Anthony J Croatt; Elena Frank; Noel M Caplice; Robert P Hebbel; Zvonimir S Katusic
Journal:  Am J Pathol       Date:  2005-04       Impact factor: 4.307

8.  Comparison of renal function markers in Kuwaiti patients with sickle cell disease.

Authors:  R Marouf; O Mojiminiyi; N Abdella; M Kortom; H Al Wazzan
Journal:  J Clin Pathol       Date:  2006-04       Impact factor: 3.411

9.  Clinical and metabolomic risk factors associated with rapid renal function decline in sickle cell disease.

Authors:  Julia Z Xu; Melanie E Garrett; Karen L Soldano; Sean T Chen; Clary B Clish; Allison E Ashley-Koch; Marilyn J Telen
Journal:  Am J Hematol       Date:  2018-09-27       Impact factor: 10.047

10.  Adverse effects of a clinically relevant dose of hydroxyurea used for the treatment of sickle cell disease on male fertility endpoints.

Authors:  Kea M Jones; Mohammad S Niaz; Cynthia M Brooks; Shannon I Roberson; Maria P Aguinaga; Edward R Hills; Valerie Montgomery Rice; Phillip Bourne; Donald Bruce; Anthony E Archibong
Journal:  Int J Environ Res Public Health       Date:  2009-03-16       Impact factor: 3.390

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.